Table 1.

Characteristics of retinopathy of prematurity patients receiving intravitreal bevacizumab (IVB) or panretinal photocoagulation (PRP).^*

	IVB	PRP	P value
No of eyes (patients)	22 (11)	32 (17)
- Zone 1	16 (8)	5 (3)
- Zone 2	6 (3)	27 (14)
Mean birth age (weeks)	24.2 ± 1.0 (23–26)	24.8 ± 1.2 (23–28)
- Zone 1	24.3 ± 1.0 (23–26)	24.4 ± 0.0 (24–24)	0.70
- Zone 2	24.0 ± 1.0 (23–25)	24.9 ± 1.3 (23–28)	0.26
Mean birth weight (g)	668.1 ± 127.3 (473–850)	701.4 ± 118.8 (525–970)
- Zone 1	667.6 ± 117.4 (515–850)	697.7 ± 89.6 (629–799)	0.70
- Zone 2	669.3 ± 181.2 (473–830)	702.2 ± 127.0 (525–970)	0.71
Male sex (%)	55%	76%	0.24
- Zone 1	63%	100%
- Zone 2	33%	71%
Mother's race (%)			0.13
- Black	45%	41%
- White	27%	35%
- Hispanic	0%	23%
- Asian	18%	0%
- Other	9%	0%
Comorbidities (%)			0.21
Intraventricular hemorrhage	64%	47%
- Grade I	27%	0%
- Grade II	18%	12%
- Grade III	9%	18%
- Grade IV	1%	18%
Necrotizing enterocolitis requiring surgery	73%	59%
Sepsis with positive cultures	45%	41%
Patent ductus arteriosus corrected with ligation	18%	18%
Mean Apgar score - 1 min	3.1 ± 2.5 (1–8)	3.8 ± 2.1 (1–7)
- Zone 1	3.5 ± 2.9 (1–8)	5.0 ± 2.0 (3–7)	0.43
- Zone 2	2.0 ± 1.0 (1–3)	3.6 ± 2.1 (1–7)	0.23
Mean Apgar score - 5 min	5.8 ± 2.0 (2–8)	6.3 ± 2.4 (1–9)
- Zone 1	6.3 ± 1.8 (4–8)	7.3 ± 1.5 (6–9)	0.37
- Zone 2	4.7 ± 2.5 (2–7)	6.1 ± 2.6 (1–9)	0.31
Mean age at treatment (PMA)	35.1 ± 2.2 (31.7–38.0)	36.1 ± 2.3 (32.7–39.9)
- Zone 1	34.9 ± 2.2 (31.7–38.0)	33.6 ± 0.8 (32.7–34.1)	0.76
- Zone 2	35.5 ± 2.7 (32.4–37.6)	37.4 ± 2.0 (33.4–39.9)	0.58
Follow-up period (months)	21.7 ± 8.8 (9.8–33.7)	34.5 ± 20.4 (6.8–72.8)
- Zone 1	19.1 ± 8.1 (9.8–33.7)	38.6 ± 20.7 (14.9–52.8)	0.04
- Zone 2	28.8 ± 7.5 (20.2–33.7)	33.7 ± 21.0 (6.8–72.8)	0.52

^*Data represent mean ± standard deviation (range) unless otherwise noted.